Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06618313

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

Led by Beijing GoBroad Hospital · Updated on 2025-06-03

8

Participants Needed

1

Research Sites

87 weeks

Total Duration

On this page

Sponsors

B

Beijing GoBroad Hospital

Lead Sponsor

R

Ruijin Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

CONDITIONS

Official Title

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Cytologically or histopathologically confirmed CD19-positive B-cell Hodgkin lymphoma based on WHO 2022 criteria, including diffuse large B-cell lymphoma, follicular lymphoma, histologically transformed lymphoma, primary mediastinal large B-cell lymphoma, or high-grade B-cell lymphoma
  • ECOG performance status of 0 or 1
  • Presence of measurable lesions meeting Lugano 2014 criteria: nodal lesions over 15 mm long axis or extra-nodal lesions over 10 mm long and short axes
Not Eligible

You will not qualify if you...

  • History of other malignant tumors within 5 years before screening, except adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local radical prostatectomy, radical ductal carcinoma in situ, or radical thyroidectomy
  • Active primary or secondary central nervous system involvement by B-cell non-Hodgkin lymphoma
  • Life expectancy less than 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Lymphoma and Myeloma, Yuhengnan Road, Changping District, Beijing

Beijing, China

Actively Recruiting

Loading map...

Research Team

K

Kai Hu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL | DecenTrialz